The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia
Abstract
Oxytocin has numerous prosocial and antipsychotic-like effects in animals. Prosocial effects of acute intranasal oxytocin administration have also been reported in human subjects. We conducted a randomized, placebo-controlled trial testing the effects of twice daily intranasal oxytocin treatment for 14 days on psychotic symptoms and social cognition in patients with schizophrenia. PANSS scores declined significantly and several social cognition measures improved significantly or nearly significantly in oxytocin (N=11) but not placebo (N=9) recipients. Our results suggest that, in addition to reducing classic psychotic symptoms, oxytocin may diminish certain social cognition deficits that are not improved by current antipsychotic medications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The acute effects of intranasal OT that we found here resemble those found in many human studies, consisting of an increase in pro-social behavior and engagement (specifically time spent in contact in males)(13,15,64–66).”
From Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles (2013) · cites this paper as [15]
In the citing paper
“while some studies among patients with other psychiatric disorders (e.g., autism, alcohol use disorder) have utilized a repeated dosing strategy in the form of 1–3 daily doses, most of these studies are only 8 days or less (Dadds et al., 2014; Guastella et al., 2015; Pedersen et al., 2011).”
From Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial (2018) · cites this paper as Pedersen et al., 2011
In the citing paper
“Safety and feasibility of daily dosing has been demonstrated in other human OT studies including those with alcohol-dependent patients (Pedersen et al., 2013), patients with schizophrenia (Pedersen et al., 2011) and individuals with trauma exposure (van Zuiden et al., 2016).”
From Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial (2018) · cites this paper as Pedersen et al., 2011
In the citing paper
“Support for the notion that an effect size of d = 0.4 adequately reflects the potential of oxytocin to reduce psychiatric symptoms stems from 2 previous studies on long-term intranasal oxytocin administration in the treatment of positive and negative symptoms in schizophrenia patients [61,97].”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [97]
In the citing paper
“The observed effect sizes were between d = 0.05 - 0.88 [97] and d = 0.24 -.74 (for most outcomes around d = 0.4) [61], depending on the outcome measure.”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [97]
In the citing paper
“Noteworthy, oxytocin treatment greatly reduced anxiety symptoms in schizophrenic patients (d = 0.62) [97].”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [97]
In the citing paper
“Previous research has shown modest effects of OT on people suffering from social deficits, such as autism spectrum disorders (Hollander et al., 2007), schizophrenia (Pedersen et al., 2011) or social anxiety disorder (Guastella et al., 2009).”
From OT promotes closer interpersonal distance among highly empathic individuals (2015) · cites this paper as Pedersen et al., 2011
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Frith, C., & Frith, U. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.041 · Cited by 3,561
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Fett, A.-K. J., Viechtbauer, W., Dominguez, M.-D.-G., Penn, D. L., van Os, J., & Krabbendam, L. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.001 · Cited by 1,833
The Functional Significance of Social Cognition in Schizophrenia: A Review
Couture, S. M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl029 · Cited by 1,363
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
The human amygdala in social judgment
Adolphs, R., Tranel, D., & Damasio, A. R. (1998) · Nature · doi:10.1038/30982 · Cited by 1,125
Oxytocin: The Great Facilitator of Life
Lee, H.-J., Macbeth, A. H., Pagani, J., & Young, W. S. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.001 · Cited by 1,037
The Human Amygdala in Social Judgment
Adolphs, R., Tranel, D., & Damásio, A. R. (2002) · The MIT Press eBooks · doi:10.7551/mitpress/3077.003.0027 · Cited by 881
Paranoia and self-consciousness.
Fenigstein, A., & Vanable, P. (1992) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.62.1.129 · Cited by 643
Cited by
Sorted by citations
Items 101–200 of 305
A Role for Oxytocin in the Etiology and Treatment of Schizophrenia
Rich, M. E., & Caldwell, H. K. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00090 · Cited by 60
Jarskog, L. F., Pedersen, C. A., Johnson, J. L., Hamer, R. M., Rau, S. W., Elliott, T., & Penn, D. L. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.01.008 · Cited by 56
Strauss, G. P., Keller, W. R., Koenig, J. I., Gold, J. M., Ossenfort, K. L., & Buchanan, R. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.023 · Cited by 54
Bartholomeusz, C. F., Ganella, E. P., Labuschagne, I., Bousman, C., & Pantelis, C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.007 · Cited by 54
Korver‐Nieberg, N., Berry, K., Meijer, C. J., de Haan, L., & Ponizovsky, A. M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.04.018 · Cited by 56
Oxytocin Selectively Improves Empathic Accuracy: A Replication in Men and Novel Insights in Women
Bartz, J. A., Nitschke, J. P., Krol, S. A., & Tellier, P. (2019) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.01.014 · Cited by 64
Kompier, N. F., Keysers, C., Gazzola, V., Lucassen, P. J., & Krugers, H. J. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00143 · Cited by 53
Walss‐Bass, C., Fernandes, J. M., Roberts, D. L., Service, H., & Velligan, D. I. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.003 · Cited by 53
Oxytocin and social cognition in affective and psychotic disorders
Pérez-Rodríguez, M. M., Mahon, K., Russo, M., Ungar, A. K., & Burdick, K. E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.012 · Cited by 58
Oya, K., Matsuda, Y., Matsunaga, S., Kishi, T., & Iwata, N. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0634-9 · Cited by 52
Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia
Strauss, G. P., Keller, W. R., Koenig, J. I., Gold, J. M., Frost, K. H., & Buchanan, R. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.034 · Cited by 51
Superior mentalizing abilities of female patients with schizophrenia
Abu-Akel, A. M., & Bo, S. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.09.013 · Cited by 49
Oxytocin—a social peptide? Deconstructing the evidence
Leng, G., Leng, R., & Ludwig, M. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0055 · Cited by 51
Strauss, G. P., Keller, W. R., Koenig, J. I., Sullivan, S. K., Gold, J. M., & Buchanan, R. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.022 · Cited by 46
The neurocircuitry involved in oxytocin modulation of methamphetamine addiction
Baracz, S. J., & Cornish, J. L. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.08.001 · Cited by 46
Seeley, S. H., Chou, Y., & O'Connor, M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.011 · Cited by 43
Zheng, W., Zhu, X.-M., Zhang, Q.-E., Yang, X.-H., Cai, D.-B., Li, L., Li, X.-B., Ng, C. H., Ungvari, G. S., Ning, Y.-P., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.007 · Cited by 45
Hofmann, S. G., Fang, A., & Brager, D. N. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.039 · Cited by 44
RetractedFlanagan, J. C., Hand, A., Jarnecke, A. M., Maria, M. M. M., Brady, K. T., & Joseph, J. E. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000197 · Cited by 47
Haram, M., Tesli, M., Bettella, F., Djurovic, S., Andreassen, O. A., & Melle, I. S. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00009 · Cited by 43
Martins, D., Paduraru, M., & Paloyelis, Y. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15451 · Cited by 42
Structural basis for the activation and ligand recognition of the human oxytocin receptor
Waltenspühl, Y., Ehrenmann, J., Vacca, S., Thom, C., Medalia, O., & Plückthun, A. (2022) · Nature Communications · doi:10.1038/s41467-022-31325-0 · Cited by 42
Intrinsic, dynamic and effective connectivity among large-scale brain networks modulated by oxytocin
Jiang, X., Ma, X., Geng, Y., Zhao, Z., Zhou, F., Zhao, W., Yao, S., Yang, S., Zhao, Z., Becker, B., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117668 · Cited by 39
A human tendency to anthropomorphize is enhanced by oxytocin
Scheele, D., Schwering, C., Elison, J. T., Spunt, R., Maier, W., & Hurlemann, R. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.05.009 · Cited by 41
Fischer-Shofty, M., Shamay‐Tsoory, S., & Levkovitz, Y. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00127 · Cited by 41
Do we need oxytocin to treat schizophrenia? A randomized clinical trial
Dagani, J., Sisti, D., Abelli, M., Paolo, L. D., Pini, S., Raimondi, S., Rocchi, M., Saviotti, F. M., Scocco, P., Totaro, S., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.011 · Cited by 43
Theodoridou, A., Rowe, A. C., & Mohr, C. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00197 · Cited by 40
Buchanan, R. W., Kelly, D. L., Weiner, E., Gold, J. M., Strauss, G. P., Koola, M. M., McMahon, R. P., & Carpenter, W. T. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000720 · Cited by 41
Potasiewicz, A., Hołuj, M., Litwa, E., Gzieło, K., Socha, L., Popik, P., & Nikiforuk, A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108040 · Cited by 39
Sabé, M., Zhao, N., Crippa, A., Strauss, G. P., & Kaiser, S. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab020 · Cited by 41
Neuropeptide Systems and Schizophrenia
LaCrosse, A., & Olive, M. F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050010 · Cited by 39
Kumar, J., Vӧllm, B., & Palaniyappan, L. K. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu051 · Cited by 40
The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
Berardis, D. D., Marini, S., Iasevoli, F., Tomasetti, C., de Bartolomeis, A., Mazza, M., Valchera, A., Fornaro, M., Cavuto, M., Srinivasan, V., et al. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312020012 · Cited by 39
Oxytocin Signaling Pathway: From Cell Biology to Clinical Implications
Iovino, M., Messana, T., Tortora, A., Giusti, C., Lisco, G., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., & Triggiani, V. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200520093730 · Cited by 39
Johansson, A., Westberg, L., Sandnabba, K. N., Jern, P., Salo, B., & Santtila, P. O. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.02.009 · Cited by 37
Vingerhoets, W. A. M., Bloemen, O., Bakker, G., & van Amelsvoort, T. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00157 · Cited by 39
Intranasal administration of oxytocin increases compassion toward women
Palgi, S., Klein, E., & Shamay‐Tsoory, S. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsu040 · Cited by 36
Win‐Shwe, T., Kyi‐Tha‐Thu, C., Moe, Y., Fujitani, Y., Tsukahara, S., & Hirano, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00524 · Cited by 37
Horta de Macedo, L. R., Zuardi, A. W., Machado-de-Sousa, J. P., Chagas, M. H. N., & Hallak, J. E. C. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.07.082 · Cited by 35
Oxytocin and Behavior: Evidence for Effects in the Brain
Stevens, F. L., Wiesman, O., Feldman, R., Hurley, R. A., & Taber, K. H. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13030061 · Cited by 38
Beard, R., Singh, N., Grundschober, C., Gee, A. D., & Tate, E. W. (2018) · Chemical Communications · doi:10.1039/c8cc01400k · Cited by 37
The role of oxytocin in delay of gratification and flexibility in non-social decision making
Kapetaniou, G. E., Reinhard, M. A., Christian, P., Jobst, A., Tobler, P. N., Padberg, F., & Soutschek, A. (2021) · eLife · doi:10.7554/elife.61844 · Cited by 34
Drug repurposing and emerging adjunctive treatments for schizophrenia
Bumb, J. M., Enning, F., & Leweke, F. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032248 · Cited by 33
Gumley, A. I., Braehler, C., & MacBeth, A. M. (2014) · British Journal of Clinical Psychology · doi:10.1111/bjc.12041 · Cited by 34
RetractedComputational drug repositioning based on side-effects mined from social media
Nugent, T., Plachouras, V., & Leidner, J. L. (2016) · PeerJ Computer Science · doi:10.7717/peerj-cs.46 · Cited by 34
Woolley, J. D., Chuang, B., Fussell, C., Scherer, S. J., Biagianti, B., Fulford, D., Mathalon, D. H., & Vinogradov, S. (2017) · Psychological Medicine · doi:10.1017/s0033291716003433 · Cited by 36
Animal-assisted therapy for schizophrenia and related disorders: A systematic review
Hawkins, E. L., Hawkins, R. D., Dennis, M. S., Williams, J. M., & Lawrie, S. M. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.013 · Cited by 34
Green, M. F., Lee, J., & Ochsner, K. N. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt131 · Cited by 33
Abu-Akel, A. M., Fischer-Shofty, M., Levkovitz, Y., Jean Decety, A., & Shamay‐Tsoory, S. (2014) · Psychological Medicine · doi:10.1017/s003329171400097x · Cited by 33
Oxytocin and interpersonal relationships
Patin, A., Scheele, D., & Hurlemann, R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_22 · Cited by 32
Schwartz, S. S., Gallagher, R. J., & Berkson, G. (1986) · PubMed · Cited by 32
Brambilla, M., Cotelli, M., Manenti, R., Dagani, J., Sisti, D., Rocchi, M., Balestrieri, M., Pini, S., Raimondi, S., Saviotti, F. M., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.08.001 · Cited by 32
Patin, A., & Hurlemann, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_10 · Cited by 37
Halverson, T. F., Jarskog, L. F., Pedersen, C. A., & Penn, D. L. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.013 · Cited by 31
Neurobiology and treatment of social cognition in schizophrenia: Bridging the bed-bench gap
Kimoto, S., Makinodan, M., & Kishimoto, T. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.022 · Cited by 33
Ahmed, M., Malik, M., Teselink, J., Lanctôt, K. L., & Herrmann, N. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00668-7 · Cited by 29
Guastella, A. J., Hermens, D. F., van Zwieten, A., Naismith, S. L., Lee, R. S. C., Cacciotti‐Saija, C., Scott, E. M., & Hickie, I. B. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.06.006 · Cited by 29
Oxytozin: Evidenz für ein therapeutisches Potenzial des sozialen Neuromodulators
Eckstein, M., & Hurlemann, R. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3832-6 · Cited by 28
Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis
Davies, C., Paloyelis, Y., Rutigliano, G., Cappucciati, M., Micheli, A. D., Ramella‐Cravaro, V., Provenzani, U., Antoniades, M., Modinos, G., Oliver, D., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0311-6 · Cited by 28
Coster, L. D., Lin, L. D., Mathalon, D. H., & Woolley, J. D. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0417-5 · Cited by 31
Remédiation cognitive des troubles de la cognition sociale dans la schizophrénie
Peyroux, É., Gaudelus, B., & Franck, N. (2013) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2013.01.003 · Cited by 27
The effects of adjunctive intranasal oxytocin in patients with schizophrenia
Ota, M., Yoshida, S., Nakata, M., Yada, T., & Kunugi, H. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1398592 · Cited by 27
Newer antipsychotics and upcoming molecules for schizophrenia
George, M., Amrutheshwar, R., Rajkumar, R. P., Kattimani, S., & Dkhar, S. A. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1498-4 · Cited by 26
Moy, S. S., Teng, B. L., Nikolova, V. D., Riddick, N. V., Simpson, C. D., Deusen, A. L. V., Janzen, W. P., Sassano, M. F., Pedersen, C. A., & Jarstfer, M. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.036 · Cited by 26
Oxytocin promotes altruistic punishment
Aydogan, G., Furtner, N. C., Kern, B., Jobst, A., Müller, N., & Kocher, M. G. (2017) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsx101 · Cited by 25
A predictive coding account of psychotic symptoms in autism spectrum disorder
van Schalkwyk, G. I., Volkmar, F. R., & Corlett, P. R. (2017) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-017-3065-9 · Cited by 25
Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats
Roberts, B. Z., Young, J. W., He, Y. V., Cope, Z. A., Shilling, P. D., & Feifel, D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.028 · Cited by 24
Are We There Yet? The Clinical Potential of Intranasal Oxytocin in Psychiatry
Liu, J. C., McErlean, R. A., & Dadds, M. R. (2012) · Current Psychiatry Reviews · doi:10.2174/157340012798994902 · Cited by 25
Lee, M. R., Wehring, H. J., McMahon, R. P., Liu, F., Linthicum, J., Verbalis, J. G., Buchanan, R. W., Strauss, G. P., Rubin, L. H., & Kelly, D. L. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.014 · Cited by 24
Kosaki, Y., & Watanabe, S. (2016) · Behavioral Neuroscience · doi:10.1037/bne0000139 · Cited by 28
Guercio, G. D., Thomas, M. E., Cisneros-Franco, J. M., Voss, P., Panizzutti, R., & de Villers‐Sidani, E. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.04.028 · Cited by 22
Strauss, G. P., Granholm, E. L., Holden, J. L., Ruiz, I., Gold, J. M., Kelly, D. L., & Buchanan, R. W. (2018) · Psychological Medicine · doi:10.1017/s0033291718002465 · Cited by 25
Alternative pharmacologic targets for the treatment of schizophrenia
Miyamoto, S., Jarskog, L. F., & Fleischhacker, W. W. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835d8296 · Cited by 23
Clinical and therapeutic role of mentalization in schizophrenia—a review
Dimopoulou, T., Tarazi, F. I., & Tsapakis, E.-M. (2017) · CNS Spectrums · doi:10.1017/s1092852916000687 · Cited by 25
Potential therapeutic avenues to tackle social cognition problems in schizophrenia
Brown, E. C., Taş, C., & Brüne, M. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.183 · Cited by 23
Social cognition across the schizophrenia–bipolar disorder spectrum
Lewandowski, K. E., Pinkham, A. E., & Rheenen, T. E. V. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-023-00269-7 · Cited by 25
L’ocytocine et la dépression du post-partum
Cardaillac, C., Rua, C., Simon, E. G., & El‐Hage, W. (2016) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2016.05.002 · Cited by 23
Chen, T., Hsieh, T., Chen, M., Tseng, W., Hung, C., & Chen, C.-R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.713623 · Cited by 28
Oxytocin and Social Cognitions in Schizophrenia: A Systematic Review
Bukovskaya, O., & Shmukler, A. B. (2015) · Psychiatric Quarterly · doi:10.1007/s11126-015-9407-x · Cited by 24
Socio-neuro risk factors for suicidal behavior in criminal offenders with psychotic disorders
Harenski, C. L., Brook, M. A., Kosson, D. S., Bustillo, J., Harenski, K. A., Caldwell, M. F., Rybroek, G. J. V., Koenigs, M. R., Decety, J., Thornton, D. M., et al. (2016) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsw164 · Cited by 22
Phospholipase C-β1 and schizophrenia-related behaviors
Koh, H.-Y. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.08.002 · Cited by 21
The Role of Oxytocin in Antisocial Personality Disorders: A Systematic Review of the Literature
Gedeon, T., Parry, J., & Vӧllm, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00076 · Cited by 20
Abram, S. V., Coster, L. D., Roach, B. J., Mueller, B. A., van Erp, T. G. M., Calhoun, V. D., Preda, A., Lim, K. O., Turner, J. A., Ford, J. M., et al. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz091 · Cited by 18
The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia
Broniarczyk-Czarniak, M., Szemraj, J., Śmigielski, J., & Gałecki, P. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44010025 · Cited by 16
Balıkçı, K., Aydın, O., Taş, C., & Danacı, A. E. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1387405 · Cited by 17
Romero‐Martínez, Á., Sarrate‐Costa, C., & Moya‐Albiol, L. (2021) · Biology · doi:10.3390/biology10121334 · Cited by 19
Reproductive experiential regulation of cognitive and emotional resilience
Kinsley, C. H., Bales, K. L., Bardi, M., & Stolzenberg, D. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.015 · Cited by 20
Yu, H., Ni, P., Zhao, L., Tian, Y., Li, M., Li, X., Wei, W., Wei, J., Deng, W., Du, X., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1180720 · Cited by 16
Chapter 4. Psychoneuroendocrinology
Sforzini, L., Weston, F. I., & Pariante, C. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as04 · Cited by 16
Marazziti, D., Diep, P.-T., Carter, C. S., & Carbone, M. G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220727120646 · Cited by 16
Goh, K. K., & Lu, M. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.013 · Cited by 18
Moslemi, M., Khodagholi, F., Asadi, S., Rafiei, S., & Motamedi, F. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112354 · Cited by 15
Waltenspühl, Y., Jeliazkov, J. R., Kummer, L., & Plückthun, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-87793-9 · Cited by 13
Tseng, H. C., Chi, M. H., Lee, L.-T., Tsai, H. C., Lee, I. H., Chen, K. C., Yang, Y. K., & Chen, P. S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.12.011 · Cited by 14
Hellemann, G., Green, M. F., Kern, R. S., Sitarenios, G., & Nuechterlein, K. H. (2017) · Psychological Medicine · doi:10.1017/s0033291717001052 · Cited by 14
Nass, S. R., Lark, A. R. S., Hahn, Y. K., McLane, V. D., Ihrig, T. M., Contois, L. W., Napier, T. C., Knapp, P. E., & Hauser, K. F. (2021) · Hormones and Behavior · doi:10.1016/j.yhbeh.2021.105008 · Cited by 14
Wigton, R. L., Tracy, D. K., Verneuil, T., Johns, M., White, T. P., Michalopoulou, P. G., Averbeck, B. B., & Shergill, S. S. (2021) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2021.100221 · Cited by 14
Pedersen, C. A., Chang, S. W. C., & Williams, C. L. (2014) · Brain Research · doi:10.1016/j.brainres.2014.07.033 · Cited by 17
Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging
Singh, N., Veronese, M., O’Doherty, J., Sementa, T., Bongarzone, S., Cash, D., Simmons, C., Arcolin, M., Marsden, P. K., Gee, A. D., et al. (2018) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2018.08.005 · Cited by 14
Lee, M. R., Wehring, H. J., McMahon, R. P., Liu, F., Linthicum, J., Buchanan, R. W., Strauss, G. P., Rubin, L. H., & Kelly, D. L. (2019) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20190001 · Cited by 14
Metadata
- Authors
- Pedersen, C. A., Gibson, C. M., Rau, S. W., Salimi, K., Smedley, K. L., Casey, R. L., Leserman, J., Jarskog, L. F., & Penn, D. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Pedersen, Cort A.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 132
- Issue
- 1
- Pages
- 50-53
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W1974375338
- Cited by
- 305
- References
- 29
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 8 · 2023: 13 · 2022: 9 · 2021: 18 · 2020: 9 · 2019: 19 · 2018: 17 · 2017: 25 · 2016: 35 · 2015: 36 · 2014: 34 · 2013: 51 · 2012: 23
- FWCI
- 47.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- National Institute of Mental Health (R01MH093529)
- National Center for Research Resources (UL1RR025747)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- intranasal oxytocin, schizophrenia
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Analysis of Variance, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Oxytocin, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Social Perception, Antipsychotic Agents, Treatment Outcome, Young Adult, Theory of Mind
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
